Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 20 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors at 7 institutions in 2 countries.
Stefano SainasDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0001-5010-8536
Marta GiorgisDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-3282-1220
Paola CircostaDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy.ORCID 0000-0001-8251-6905
Giulio PoliDepartment of Pharmacy, University of Pisa, Via Bonanno 6, Pisa 56126, Italy.
Marta AlbertiDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, Via G. Bovio 6, Novara 28100, Italy.ORCID 0000-0003-3827-7243
Alice PassoniLaboratory of Mass Spectrometry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.ORCID 0000-0001-6003-5932
Valentina GaidanoDivision of Hematology and Cell Therapy, AO Ordine Mauriziano, Largo Filippo Turati, 62, Turin 10128, Italy.ORCID 0000-0003-0701-7975
Agnese C PippioneDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0003-3778-8420
Nicoletta VitaleDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin 10126, Italy.
Davide BonanniDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-8832-0492
Barbara RolandoDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0001-6138-1503
Alessandro CignettiDivision of Hematology and Cell Therapy, AO Ordine Mauriziano, Largo Filippo Turati, 62, Turin 10128, Italy.ORCID 0000-0003-2109-1194
Cristina RamondettiDepartment of Oncology, University of Turin, Via Michelangelo 27/B, Turin 10125, Italy.ORCID 0000-0002-0501-5696
Alessia LannoLaboratory of Mass Spectrometry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy.ORCID 0000-0002-3473-8877
Davide M FerrarisDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, Via G. Bovio 6, Novara 28100, Italy.
Barbara CanepaGEM FORLAB, Via Ing. Comotto 36, Caluso, Turin, 10014, Italy.
Barbara BuccinnàDepartment of Oncology, University of Turin, Via Michelangelo 27/B, Turin 10125, Italy.ORCID 0000-0002-5843-7112
Marco PiccininiDepartment of Oncology, University of Turin, Via Michelangelo 27/B, Turin 10125, Italy.ORCID 0000-0003-2287-0704
Menico RizziDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, Via G. Bovio 6, Novara 28100, Italy.
Giuseppe SaglioDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy.ORCID 0000-0002-1046-3514
Salam Al-KaradaghiDepartment of Biochemistry and Structural Biology, Lund University, Naturvetarvägen 14, Box 124, Lund 221 00, Sweden.ORCID 0000-0001-8608-0635
Donatella BoschiDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0003-4929-4460
Riccardo MiggianoDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, Via G. Bovio 6, Novara 28100, Italy.
Tiziano TuccinardiMolecular Biotechnology Center, University of Turin, Via Nizza 52, Turin 10126, Italy.ORCID 0000-0002-6205-4069
Marco L LolliDepartment of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy.ORCID 0000-0002-3030-3163
University of Turin · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITA. O. Ordine Mauriziano di Torino · ITMario Negri Institute for Pharmacological Research · ITLund University · SEUniversity of Modena and Reggio Emilia · ITUniversity of Pisa · IT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
In recent years, human dihydroorotate dehydrogenase inhibitors have been associated with acute myelogenous leukemia as well as studied as potent host targeting antivirals. Starting from MEDS433 (IC
Indexed as
Leukemia, Myeloid, AcuteOxidoreductases Acting on CH-CH Group DonorsAnimalsAntiviral AgentsDihydroorotate DehydrogenaseDipyridamoleEnzyme InhibitorsHumansMicePyrazolonesPyridinesStructure-Activity RelationshipAntiviral AgentsDihydroorotate DehydrogenaseDipyridamoleEnzyme InhibitorsMEDS433Oxidoreductases Acting on CH-CH Group DonorsPyrazolonesPyridines
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- · full record | OpenQuestion